Cancers, Free Full-Text

The field of cancer research is famous for its incremental steps in improving therapy. The consistent but slow rate of improvement is greatly due to its meticulous use of consistent cancer biology models. However, as we enter an era of increasingly personalized cancer care, including chemo and radiotherapy, our cancer models must be equally able to be applied to all individuals. Patient-derived organoid (PDO) and organ-in-chip (OIC) models based on the micro-physiological bioengineered platform have already been considered key components for preclinical and translational studies. Accounting for patient variability is one of the greatest challenges in the crossover from preclinical development to clinical trials and patient derived organoids may offer a steppingstone between the two. In this review, we highlight how incorporating PDO’s and OIC’s into the development of cancer therapy promises to increase the efficiency of our therapeutics.

Kidney Cancer Text · Free Stock Photo

Frailty and prognosis in lung cancer: systematic review and meta

Prognostic implications of p16 and HPV discordance in

Information and Resources about for Cancer: Breast, Colon, Lung

from Flow Cytometry to Cytomics, Page 2

Immunotherapy approaches for hematological cancers - ScienceDirect

Hallmarks of Cancer: The Next Generation: Cell

O Amar Mota Bou Get File - Colaboratory

Cancers, Free Full-Text